Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Colorcon
Medtronic
McKesson
Harvard Business School

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Rigosertib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Rigosertib: Sponsors, patents, clinical trial progress

Rigosertib is an investigational drug.

There have been 27 clinical trials for Rigosertib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Syndrome, Preleukemia, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Onconova Therapeutics, Inc., M.D. Anderson Cancer Center, and Academic Oncology Gastrointestinal Cancer Consortium (AGICC).

There are thirteen US patents protecting this investigational drug and seventy-eight international patents.

Recent Clinical Trials for Rigosertib
TitleSponsorPhase
Rigosertib for RDEB-SCCProf. Johann BauerPhase 1/Phase 2
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and AnemiaOnconova Therapeutics, Inc.Phase 2
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and AnemiaM.D. Anderson Cancer CenterPhase 2

See all Rigosertib clinical trials

Clinical Trial Summary for Rigosertib

Top disease conditions for Rigosertib
Top clinical trial sponsors for Rigosertib

See all Rigosertib clinical trials

US Patents for Rigosertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Rigosertib   See Pricing Formulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones ONCONOVA THERAPEUTICS, INC. (Newtown, PA)   See Pricing
Rigosertib   See Pricing Substituted alkyl diaryl derivatives, methods of preparation and uses TEMPLE UNIVERSITY--Of The Commonwealth System of Higher Education (Philadelphia, PA)   See Pricing
Rigosertib   See Pricing Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders Temple University - Of the Commonwealth System of Higher Education (Philadelphia, PA) Onconova Therapeutics, Inc. (Newtown, PA)   See Pricing
Rigosertib   See Pricing Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones Onconova Therapeutics, Inc. (Newtown, PA)   See Pricing
Rigosertib   See Pricing Composition and methods for the treatment of proliferative diseases Temple University - Of The Commonwealth System of Higher Education (Philadelphia, PA) Mount Sinai School of Medicine (New York, NY)   See Pricing
Rigosertib   See Pricing Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis Temple University--Of The Commonwealth System of Higher Education (Philadelphia, PA) Onconova Therapeutics, Inc. (Newtown, PA)   See Pricing
Rigosertib   See Pricing Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones Temple University--Of The Commonwealth System of Higher Education (Philadelphia, PA) Onconova Therapeutics, Inc. (Newtown, PA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rigosertib

Drugname Country Document Number Estimated Expiration Related US Patent
Rigosertib Argentina 109503 2037-04-13   See Pricing
Rigosertib Taiwan 201836597 2037-04-13   See Pricing
Rigosertib Uruguay 37380 2037-04-13   See Pricing
Rigosertib World Intellectual Property Organization (WIPO) 2018190897 2037-04-13   See Pricing
Rigosertib World Intellectual Property Organization (WIPO) 2018191634 2037-04-13   See Pricing
Rigosertib Australia 2013318206 2032-09-20   See Pricing
Rigosertib Canada 2885217 2032-09-20   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Mallinckrodt
Johnson and Johnson
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.